AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Other Financing Activities

Financing cash flows not reported separately.

AC Immune S.A.NASDAQ: ACIU

Other Financing Activities · Q4 FY2025 · quarter ended Dec 2025

Other financing activities turns positive

Q4 FY2025 other financing activities was CHF 1.03K, compared with -CHF 1K a year earlier. Trailing-twelve-month other financing activities was CHF 1.03K.

Context

  • Other financing activities amounted to 1.3% of revenue in FY2025, down 0.7 pp from a year earlier.
  • Other financing activities increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other financing activities holds near CHF 1.03K or moves back toward the trailing-twelve-month quarterly average of CHF 257.5.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
CHF 1.03K— QoQ
Last fiscal yearDec 2025
CHF 46.13K+108.4% YoY
LTMDec 2025
CHF 1.03K+100.2% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+203.0%——
1 year+108.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

CHF · from the cash flow

Latest · FY2025
46.13K CHF
Year-over-year change
+108.4%

Other Financing Activities vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +100.2% is the 5th highest of 8, against a peer median of +117.1%.
  • Other financing activities amounts to 0.0% of revenue for ACIU, versus a peer median of 6.5%.
ACIU Competitors
Other Financing Activities for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$6.49M USD+95.6%—9.5%
AMRNAmarin Corporation plcLTM Mar 2026$2.73M USD+117.1%+27.8%1.3%
ANNXAnnexon, Inc.LTM Mar 2026$273K USD+325.6%——
ANROAlto Neuroscience, Inc.LTM Mar 2026$229K USD+141.9%——
MREOMereo BioPharma Group plcLTM Mar 2026$134K USD-100.3%—26.8%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$104K USD+333.3%——
LYELLyell Immunopharma, Inc.LTM Mar 2026$2K USD-300.0%-87.1%6.5%
ACIUAC Immune S.A.LTM Dec 2025CHF 1.03K CHF+100.2%—0.0%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$0 USD———
SLNSilence Therapeutics plcLTM Mar 2026$0 USD——0.0%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ACIU) —+117.1%-29.6%6.5%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.